Patents
Literature
5291 results about "Immunology" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Immunology is a branch of biology that covers the study of immune systems in all organisms. Immunology charts, measures, and contextualizes the physiological functioning of the immune system in states of both health and diseases; malfunctions of the immune system in immunological disorders (such as autoimmune diseases, hypersensitivities, immune deficiency, and transplant rejection); and the physical, chemical, and physiological characteristics of the components of the immune system in vitro, in situ, and in vivo. Immunology has applications in numerous disciplines of medicine, particularly in the fields of organ transplantation, oncology, rheumatology, virology, bacteriology, parasitology, psychiatry, and dermatology.
Methods and systems for intelligent conversational assistant
PendingUS20260023787A1Natural language translationDigital data information retrievalTesting MethodsMultiple applications
Described herein are methods and systems for a conversational assistant that may be configured for use with one or more applications. The disclosed systems and methods may be configured as an outer loop / inner loop architecture incorporating one or more large language models (LLMs) and / or RAG functionality to support dialog-based interactions.
Owner:SUVODA LLC
Anti-GAL3 antibodies and uses thereof
Disclosed herein are antibodies that specifically bind to Gal3 and methods of use thereof. In some embodiments, also described herein are methods of inducing immune activation or promoting T cell or Natural Killer cell proliferation with an antibody that specifically binds to Gal3. Also disclosed herein are methods and compositions of reducing fibrosis or propensity thereof in a tissue with antibodies that specifically bind to Gal3. In some cases, the anti-Gal3 antibody also disrupts the interaction between Gal3 and TIM-3.
Owner:TRUEBINDING INC
Application of reagent for targeted inhibition of circPDK1 in preparation of anti-esophageal cancer drugs
The invention relates to application of a targeted inhibition circPDK1 reagent in preparation of an anti-esophageal cancer drug, and belongs to the field of biological medicines. The reagent for targeted inhibition of circPDK1 expression provided by the invention is shRNA or siRNA, and in-vivo and in-vitro experiments prove that the reagent can significantly inhibit circPDK1 expression and inhibit growth and migration of esophageal cancer tumor cells; after siRNA of targeted annular circPDK1 is packaged into efficient and low-toxicity LNP-siRNA, circPDK1 expression is specifically silenced, proliferation and migration of esophageal cancer tumors can be remarkably inhibited, and a basis is provided for clinical treatment and scientific research of esophageal cancer related circRNA.
Owner:KUNMING MEDICAL UNIVERSITY
Subcutaneous formulations of anti-CD38 antibodies and their uses
ActiveUS12583936B2Peptide/protein ingredientsInorganic non-active ingredientsAntiendomysial antibodiesBiochemistry
Owner:JANSSEN BIOTECH INC
Novel anti-human DKK-1 monoclonal antibody
The invention provides a novel anti-human DKK-1 monoclonal antibody, aiming at solving the problems that osteoporosis antibody drugs developed in China at present are biosimilar drugs, and the existing antibody drugs also have certain defects, for example, Romosozumab is easy to cause cardiovascular adverse reactions, and DKK-1 antibody drugs aiming at osteoporosis do not appear on the market globally. According to the present invention, the rarely researched DKK-1 is adopted as the target spot to research the humanized DKK-1 antibody, such that the foundation is laid for the clinic and the effectiveness of the DKK-1 antibody, the treatment approach with the excellent effect is provided for the patient, and the problem of the lack of the innovation of the domestic antibody drug for treating osteoporosis can be hopefully solved.
Owner:TAIZHOU MABTECH PHARM CO LTD
TP53 mutation resistant T cell receptor and application thereof
InactiveCN121202998AImmunoglobulin superfamilyGenetically modified cellsComplementarity determining regionOncology
The invention discloses an anti-TP53 mutation T cell receptor and application thereof, the T cell receptor comprises specific alpha chain and beta chain variable domains, and the complementary determining region (CDR) sequence is shown as SEQ ID NO: 9-14. The TCR has the core advantage that the TCR has excellent broad-spectrum recognition capability, can target six different amino acid substitutions (A, G, I, N, S and T) at the R249 site, and effectively deals with tumor heterogeneity and mutation difference between patients. Aiming at high-frequency HLA-B * 07: 02 alleles in people, the TCR lays a foundation for developing TCR-T cell therapy covering a wide range of people, and has great clinical application value and market potential in treatment of various solid tumors carrying TP53 R249 hotspot mutation, such as liver cancer.
Owner:SUZHOU INST OF SYST MEDICINE
BTK degrader and use thereof
The present disclosure relates to compounds that function as degraders or inhibitors of BTK. The present disclosure further relates to pharmaceutical compositions comprising them, and to their use in the treatment of diseases mediated by BTK, such as cancer.
Owner:ASCENTAGE PHARMA SUZHOU CO LTD +1
Klebsiella aerogenes HW2024 and application thereof in preparation of medicine for treating allergic rhinitis
The invention discloses klebsiella aerogenes HW2024 and application of the klebsiella aerogenes HW2024 in preparation of drugs for treating allergic rhinitis. The preservation number of the klebsiella aerogenes HW2024 is CCTCC NO: M 20252524. The Klebsiella aerogenes disclosed by the invention is a symbiotic bacterium, and is relatively safe and easy to obtain, so that the treatment cost of AR patients can be greatly reduced, and a new treatment choice is provided for AR treatment; the pharmaceutical preparation for treating allergic rhinitis is simple and convenient in administration route, easy to operate and convenient for patients to use.
Owner:TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
Hybridoma cell strain secreting mefos monoclonal antibody and application of hybridoma cell strain
The invention relates to a hybridoma cell strain capable of secreting a mefos monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. According to the invention, the hybridoma cell strain capable of secreting the fenofos monoclonal antibody is obtained through screening, the fenofos monoclonal antibody has high specificity and high sensitivity to the fenofos, IC50 to the fenofos is 0.231 ng / mL, and the fenofos monoclonal antibody has no cross reaction to structural analogues of the fenofos, such as triazophos, diazinon, phorate, acetyl phorate, methamidophos and the like; therefore, low-concentration isoprophos can be accurately detected.
Owner:JIANGNAN UNIV
Treatment of IgE-mediated diseases with antibodies that specifically bind CD38
ActiveUS12528878B2Organic active ingredientsPeptide/protein ingredientsDiseaseAntiendomysial antibodies
The present invention relates to treatment of IgE-mediated disease with antibodies that specifically bind CD38.
Owner:UMC UTRECHT HLDG BV
Hybridoma cell strain secreting dextromethorphan monoclonal antibody and application thereof
The invention relates to a hybridoma cell strain capable of secreting dextromethorphan monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain disclosed by the invention has good sensitivity and specificity on dextromethorphan, wherein the IC50 value on the dextromethorphan is 0.162 ng / mL. The monoclonal antibody provided by the invention has no cross reaction on structural analogues of dextromethorphan, such as fentanyl, thilazine, papaverine, morphine and medetomidine, and has good specificity, so that the dextromethorphan with low concentration can be accurately detected.
Owner:JIANGNAN UNIV
Tissue directed antibodies and methods of use thereof
PendingCN121793982AImmunoglobulin superfamilyAntibody mimetics/scaffoldsAntiendomysial antibodiesPharmacy medicine
Owner:ZAGER BIOTECH
Fully enclosed method and system for enriching natural killer cells
PCT designated stageWO2026056890A1Bioreactor/fermenter combinationsCell dissociation methodsNatural killer cellBiomedical engineering
Owner:HANGZHOU BIOGNK BIOTECHNOLOGY CO LTD
Anti-nectin-4 antibody and use thereof
PCT designated stageWO2025261506A1Antibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntiendomysial antibodiesNectin
The present invention relates to a novel antibody and antibody fragment specifically binding to Nectin-4, and a composition containing the antibody or the antibody fragment. In addition, the present invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell containing same, and a related use. Further, the present invention relates to therapeutic and diagnostic uses of the antibody and the antibody fragment.
Owner:INNOVENT BIOLOGICS (SUZHOU) CO LTD
Targeted chimeric antigen receptor modified T cells for treatment of IL13RALPHA2 positive malignancies
ActiveUS12551557B2Polypeptide with localisation/targeting motifImmunoglobulin superfamilyAntigen receptorChimeric antigen receptor
Chimeric antigen receptors targeted to IL-13Ra2 are described. The targeting domain is a IL13 variant having increased specificity for IL-13Ra2 relative to IL-13Ra1.
Owner:CITY OF HOPE
Blood-brain barrier crossing antibodies
The present invention relates to antibodies or antibody fragments that bind to human and non-human primate transferrin receptors. The antibodies described herein can be used as agents to deliver pharmaceutical compounds into or through cells during receptor-mediated endocytosis and / or transendocytosis processes. As transferrin receptors are also present in the blood brain barrier endothelial cells, one aspect of the invention provides means and methods to increase delivery of pharmaceutical compounds to the central nervous system.
Owner:VLAAMS INTERUNIVERSITAIR INST VOOR BIOTECHNOLOGIE VZW +1
Detection of autoantibodies against NR1
The present disclosure provides systems and methods for detecting anti-NMDAR autoantibodies based on the strong affinity of the anti-NMDAR autoantibodies to a plurality of non-random anti-NR1s coupled to a solid support. The present disclosure also provides methods of treatment for anti-NMDAR pathology by the therapeutic anti-NMDAR antibody ART5803. The present disclosure also provides methods and systems for screening and predicting potential responsiveness to ART5803 therapy.
Owner:ARIALYS THERAPEUTICS INC
ROR-1 specific chimeric antigen receptors and uses thereof
PendingUS20260035432A1Nucleic acid vectorImmunoglobulins against cell receptors/antigens/surface-determinantsAntiendomysial antibodiesAntigen receptors
Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-ROR-1 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.
Owner:PRECIGEN INC
CD 4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof
PCT designated stageWO2026015450A1Polypeptide with localisation/targeting motifImmunoglobulin superfamilyAntigen receptorGraft versus host disease induction
The present disclosure provides a population of CD4IL-10 / CAR cells (autologous or allogeneic single-donor and allogeneic polydonor) generated by genetically modifying CD4+ Tcells to express IL-10 and a chimeric antigen receptor. Further provided are methods of generating the CD4IL-10 / CAR cells and methods of using the CD4IL-10 / CAR cells for immune tolerization, treating GvHD, cell and organ transplantation, cancer, and autoimmune and inflammatory disorders.
Owner:TR1X INC
Fusion protein of bispecific antibody targeting T cell and Her2 in series connection with IL-15 and receptor thereof and application of fusion protein
The invention discloses a fusion protein of a bispecific antibody targeting a T cell and Her2 in series connection with IL-15 and a receptor thereof and an application of the fusion protein. Belongs to the technical field of biology. The fusion protein disclosed by the invention can be combined with a recombinant human CD3 protein and a recombinant human Her2 protein, can be combined with NK92 and SK-BR-3 cell lines, can stimulate NK92 cell proliferation, and can respectively cause ADCC effects mediated by T and NK cells; the antibody has important economic and social significance.
Owner:BEIJING ZAIQING BIOTECHNOLOGY CO LTD
System and method for monitoring of charge variants of monoclonal antibodies using raman spectroscopy
PendingUS20260056171A1Component separationSolid sorbent liquid separationAntiendomysial antibodiesBiochemistry
A system and method for determining charge variants in monoclonal antibodies using raman spectroscopy is disclosed.
Owner:CYTIVA US LLC +1
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. The methods may comprise gene-editing at least a portion of the TILs to enhance their therapeutic efficacy. Such TILs find use in therapeutic treatment regimens.
Owner:IOVANCE BIOTHERAPEUTICS INC
Combination therapy for cancer treatment
PCT designated stageWO2025257394A1Immunoglobulins against growth factorsAntibody ingredientsAntiendomysial antibodiesVEGF receptors
The invention relates to a combination of a binding agent comprising (i) a first binding region which binds to PD-1, PD-L1, or both and which antagonizes the PD-1 / PD-L1 interaction; and (ii) a second binding region which binds to VEGF, VEGF receptor (VEGFR), or both and which antagonizes the VEGF / VEGFR interaction, and an antibody-drug conjugate comprising an antibody or fragment thereof that specifically binds to a target expressed on the surface of a tumour cell.
Owner:BIONTECH SE
Antibodies binding to axl
The present invention relates to antibodies that bind AXL. The present invention relates to anti-AXL antibodies, immunoconjugates, compositions, and methods of using such anti-AXL antibodies, immunoconjugates, or compositions to treat cancer.
Owner:GENMAB AS
Fully human monoclonal antibodies against human her-2
Described herein are antibodies, particularly monoclonal antibodies, that specifically bind to human HER2 and are useful for the treatment of cancer in patients.
Owner:A&G PHARMACEUTICAL INC
Humanized antibodies to mucin-16 and methods of use thereof
ActiveUS12617866B2Peptide/protein ingredientsAntibody mimetics/scaffoldsDiseaseAntiendomysial antibodies
Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT +1
Detection method for detecting botulinum toxin A HA-70 and product
ActiveCN121522173ABiological material analysisImmunoglobulinsAntiendomysial antibodiesBotulinum toxin type
The invention discloses a detection method for detecting botulinum toxin A HA-70 and a product. The detection product disclosed by the invention comprises an antibody capable of being combined with the botulinum toxin A HA-70. The antibody has good affinity and stability, can be widely applied to detection of botulinum toxin type A HA-70, can be combined with a capillary immunoelectrophoresis method to establish a standard map for detection of botulinum toxin component antibodies, and provides a quality control means for commercialization and self-research of antibodies, so that the antibody has good application prospects. According to the method, more possibilities are provided for establishment of related botulinum toxin detection methods, and detection requirements of more scenes can be met.
Owner:LANZHOU BIOTECHNIQUE DEV CO LTD
Custom recombinant polyclonal proteins and methods of use thereof
PCT designated stageWO2026024904A1Immunoglobulins against cell receptors/antigens/surface-determinantsBioinformaticsBiochemistryLibrary
Owner:GIGAGEN INC